Intas: UDENYCA Acquisition Solidifies Global Pegfilgrastim Leadership

Intas Pharmaceuticals, through its global subsidiaries under the Accord brand, has acquired UDENYCA® (Pegfilgrastim-cbqv) from Coherus BioSciences, Inc., solidifying its position as a premier provider of Pegfilgrastim worldwide. UDENYCA®, a biosimilar of Neulasta® approved by the FDA, enhances Intas and Accord's biosimilar portfolio and advances their strategic growth in the global market. Accord, a market leader for Pegfilgrastim in Europe, has introduced this acquisition to further secure its influence in the U.S. and international biosimilar landscape. Accord BioPharma, the U.S. specialty business of Intas, continues the marketing of UDENYCA® to reduce infection rates associated with febrile neutropenia in patients undergoing myelosuppressive cancer therapy. The acquisition adds 300,000 patients to its treatment history and includes the recruitment of key Coherus BioSciences employees to ensure smooth operational transitions. Leaders from Intas and Accord underscore the acquisition's importance in innovation and market presence. Key figures such as Chrys Kokino, Paul Tredwell, and Binish Chudgar accentuate its role in expanding global capabilities in biosimilars. The strategic move brings Intas closer to its goal of becoming the top global provider of Pegfilgrastim while ensuring high-quality patient access worldwide.